Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera
暂无分享,去创建一个
[1] W. Borkowsky,et al. Growth patterns in pubertal HIV-infected adolescents and their correlation with cytokines, IGF-1, IGFBP-1, and IGFBP-3 , 2013, Journal of pediatric endocrinology & metabolism : JPEM.
[2] J. Kappes,et al. Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding , 2012, Journal of Virology.
[3] J. Guerra-Laso,et al. Non-chemotactic influence of CXCL7 on human phagocytes. Modulation of antimicrobial activity against L. pneumophila. , 2012, Immunobiology.
[4] R. Redfield,et al. Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases , 2012, Proceedings of the National Academy of Sciences.
[5] R. Ahmed,et al. T‐cell reconstitution without T‐cell immunopathology in two models of T‐cell‐mediated tissue destruction , 2009, Immunology.
[6] F. Hsieh,et al. Efficacy of Hepatitis B Immune Globulin for Prevention of Perinatal Transmission of the Hepatitis B Virus Carrier State: Final Report of a Randomized Double‐Blind, Placebo‐Controlled Trial , 2007, Hepatology.
[7] H. Katinger,et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity , 2006, AIDS.
[8] K. Ugen,et al. Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37. , 2004, DNA and cell biology.
[9] H. Katinger,et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques , 2003, AIDS.
[10] H. Katinger,et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation , 2002, AIDS.
[11] H. Katinger,et al. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.
[12] H. Katinger,et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 , 2002, AIDS.
[13] C. E. Parker,et al. Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.
[14] M Stürzl,et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. , 2001, Molecular biology of the cell.
[15] S. Zolla-Pazner,et al. Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 , 2001, Journal of Virology.
[16] Robert A. Rasmussen,et al. Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.
[17] S. Zolla-Pazner,et al. Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes , 2000, Journal of Virology.
[18] D. Weiner,et al. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. , 2000, Virology.
[19] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[20] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[21] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[22] H. Katinger,et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.
[23] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[24] Susan Zolla-Pazner,et al. Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins , 1998, Journal of Virology.
[25] S. Zolla-Pazner,et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. , 1997, International immunology.
[26] E A Emini,et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.
[27] J. Bradac,et al. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.
[28] J. Hoxie,et al. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[29] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[30] S. Zolla-Pazner,et al. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. , 1995, AIDS research and human retroviruses.
[31] J. Safrit,et al. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. , 1995, The Journal of infectious diseases.
[32] Q. Sattentau,et al. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.
[33] C. Barbas,et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.
[34] A. Trkola,et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.
[35] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[36] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[37] D. Fulton,et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children , 1994 .
[38] E. Emini,et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] C. Hall,et al. Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .
[40] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[41] W. Schleif,et al. Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.
[42] S. Zolla-Pazner,et al. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.
[43] S. Zolla-Pazner,et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. , 1990, Journal of immunology.
[44] S. Zolla-Pazner,et al. Generation of human monoclonal antibodies to human immunodeficiency virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[45] T. Lehner,et al. Use of monoclonal antibodies in local passive immunization to prevent colonization of human teeth by Streptococcus mutans , 1987, Infection and immunity.
[46] S. Sallan,et al. Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. , 1981, Cancer research.
[47] F. Hsieh,et al. HEPATITIS B IMMUNE GLOBULIN (HBIG) EFFICACY IN THE INTERRUPTION OF PERINATAL TRANSMISSION OF HEPATITIS B VIRUS CARRIER STATE Initial Report of a Randomised Double-Blind Placebo-Controlled Trial , 1981, The Lancet.